Figure S1. Study Design from Open-label, Phase I Study of Nivolumab Combined with nab-Paclitaxel Plus Gemcitabine in Advanced Pancreatic Cancer

Authors :: Peter J. O'Dwyer
Teng Jin Ong
Chrystal U. Louis
Larry Lyons
Sibabrata Banerjee
Rafia Bhore
Daniel W. Pierce
David J. Reiss
Thomas Lila
Hatem H. Soliman
Daniel Ricardo Carrizosa
Rishi Jain
Aparna Parikh
Martin Guiterrez
David M. Waterhouse
E. Gabriela Chiorean
Aparna Kaylan
Ben George
Edward J. Kim
Howard S. Hochster
Zev A. Wainberg
Publication Year :: 2023
Publisher :: American Association for Cancer Research (AACR), 2023.
Abstract: Patients were enrolled in Arm B Part 1 after the safety oversight committee deemed Arm A Part 1 safe. DRC, data review committee; LAPC, locally advanced pancreatic cancer; MPC, metastatic pancreatic cancer; RP2D, recommended Part 2 dose.

Full Text Access

Tools